Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fluorinated polymer nanoparticles for mRNA-based cancer therapy

Project description

Fluorinated nanoparticles enhance delivery of cancer-fighting mRNA to solid tumours

Translating mRNA technology from effective vaccines to cancer therapy has been hampered by poor delivery to solid tumours and variable treatment response to immunotherapies. Triple negative breast cancer – an aggressive form with limited options – exemplifies this challenge. With the support of the Marie Skłodowska-Curie Actions programme, the FluorNano project aims to revolutionise mRNA cancer therapy with fluorinated polymeric nanoparticles. The nanoparticles will deliver mRNA encoding an engineered epithelial human growth factor 2 (HER2) receptor to cancer cells. When expressed by them, HER2 will sensitise the cancer cells to existing ‘anti-HER2’ therapies. Tested in tumour models and animal studies, this approach could unlock mRNA’s potential for treating aggressive cancers with poor prognosis.

Objective

Global success of COVID-19 vaccines showcased mRNA as safe and effective tool for transient protein expression and opened avenues
for innovative applications of mRNA in cancer therapy but efficient delivery to solid tumors and variable response rates to
immunotherapies remain the major obstacles to the development of mRNA-based cancer therapeutics. FluorNano aims to
revolutionize cancer treatment by leveraging fluorine properties to enhance messenger RNA (mRNA) delivery, stability, cellular
uptake, and therapy of aggressive cancers like Triple Negative Breast Cancer (TNBC) with poor survival rates. FluorNano proposes a
novel approach that involves developing fluorinated polymers for the delivery of mRNA to TNBC to express engineered Human
Epidermal Growth Factor Receptor 2 (HER2) that can sensitize cancer cells to approved anti-HER2 therapies such as Trastuzumab and
Trastuzumab-Deruxtecan (T-DXd). FluorNano will last 2 years and will be conducted at University College of Cork, Ireland (24
months), and also involve a secondment at i3S Institute of University of Porto (4 months) to evaluate the efficacy of fluorinated NPs in
3D cancer models. The project’s main objectives are to develop a library of fluorinated polymeric mRNA NPs, assess HER2 mRNA
delivery in vitro TNBC models, and evaluate the therapeutic efficacy of mRNA-based intervention in combination with anti-HER2
therapies in animal models. FluorNano is committed to advancing cancer therapies and aligning with European missions, aiming to
make a lasting impact on cancer treatment and drive sustainable improvements in patient care. The FluorNano project will advance
my career by offering advanced training, improving my research skills, and expanding my professional network, helping me become
an independent researcher. The public and scientific community will be informed about the project’s outcomes and the benefits of
RNA-based therapies through a targeted dissemination strategy.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Net EU contribution
€ 252 728,64
Address
WESTERN ROAD
T12 YN60 Cork
Ireland
Region
Ireland Southern South-West
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)